pegIFN

DRUG2 trials

Sponsors

Bristol-Myers Squibb, GlaxoSmithKline

Conditions

Hepatitis BHepatitis B Virus

Phase 2

Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen

CompletedNCT01204762

Bristol-Myers SquibbHepatitis B Virus

Start: 2010-11-30End: 2013-12-31Updated: 2015-10-09

Study of Sequential GSK3228836 and Peginterferon Treatment in Participants With Chronic Hepatitis B (CHB)

CompletedNCT04676724

GlaxoSmithKlineHepatitis B

Start: 2021-01-28End: 2023-02-17Updated: 2024-05-02

Related Papers

Immunomodulation by bepirovirsen may induce killing of infected hepatocytes (B-Together study).

2025-10-032 citations

Sequential Peg-IFN after bepirovirsen may reduce post-treatment relapse in chronic hepatitis B.

2024-08-2923 citations

Peg-Interferon Lambda Treatment Induces Robust Innate and Adaptive Immunity in Chronic Hepatitis B Patients

Frontiers in Immunology2017-05-2967 citations

Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B).

2015-12-2984 citations